Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses (400mg, 800mg, 1200mg) of BI 207127 NA in Healthy Male Asian Volunteers and Single Oral Dose (1200 mg) of BI 207127 NA in Healthy Male Caucasian Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Group).
Phase of Trial: Phase I
Latest Information Update: 17 Apr 2016
At a glance
- Drugs Deleobuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 28 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 May 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 05 May 2011 New trial record